ReviewThe Canadian veterinary journal = La revue veterinaire canadienne2020
Recent and current clinical trials in canine appendicular osteosarcoma.
Review in The Canadian veterinary journal = La revue veterinaire canadienne, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Spatial transcriptomic mapping of canine osteosarcoma reveals immune microenvironment features linked to survival.Communications biology · 2026Article
- Losartan, toceranib, and carboplatin combination therapy for progressive pulmonary metastasis in canine osteosarcoma: a case report.Irish veterinary journal · 2026Article
- Evaluating the synergistic effects of cisplatin and tamoxifen in canine osteosarcoma cells.Frontiers in veterinary science · 2026Article
- Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma.Cancer research communications · 2025Article
- Cytotoxic and apoptotic effects of etoposide and ellagic acid alone or with possible synergistic/additive combinations on a canine D-17 osteosarcoma cell line.Veterinarni medicina · 2025Article
- Systemic strategies for osteosarcoma: advances and future directions.Discover oncology · 2025Review
- The Anti-Metastatic Properties of Glutathione-Stabilized Gold Nanoparticles-A Preliminary Study on Canine Osteosarcoma Cell Lines.International journal of molecular sciences · 2025Article
- Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017-2024).Veterinary sciences · 2025Review
- Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.Molecular therapy oncolytics · 2023Article
- Vertebral Osteosarcoma in Two Cats-Diagnosis, Treatment, and Outcome.Animals : an open access journal from MDPI · 2023Article
- A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Image-Based Dosimetry in Dogs and Cross-Reactivity with Human Tissues of IGF2R-Targeting Human Antibody.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Dog breeds and conformations predisposed to osteosarcoma in the UK: a VetCompass study.Canine medicine and genetics · 2023Article
- Long-term adjuvant metronomic chemotherapy in a dog with recurrent maxillofacial osteosarcoma.Veterinarni medicina · 2023Article
- Isolation and Characterization of Novel Canine Osteosarcoma Cell Lines from Chemotherapy-Naïve Patients.Cells · 2023Article
- Investigating cell death responses associated with histotripsy ablation of canine osteosarcoma.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2023Article
- Review
- Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.BMC cancer · 2021Article
- Targeting Mechanotransduction in Osteosarcoma: A Comparative Oncology Perspective.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OSA) is an aggressive primary bone tumor in the domestic dog that most often occurs within the appendicular skeleton. Despite the use of adjuvant chemotherapy, most dogs succumb to metastatic disease within 1 year of diagnosis. To improve this outcome, substantial research is currently focused on investigating novel therapies. Herein, we review emerging treatments and clinical trials that, if proven efficacious, could revolutionize the standard of care for canine appendicular OSA. This article includes a critical perspective on the safety, efficacy, and limitations of select immunotherapy, virotherapy, radiotherapy, targeted therapy, and personalized medicine trials, all of which reflect similar investigations taking place in human oncology. These clinical trials represent a major evolution in the overall approach to therapy for dogs with appendicular OSA that could have significant implications for improving survival.
Indexed as
Identifiers
32165755PMC7020630W3012465945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.